SLC5A2 and heart failure: These non-glycemic pathways have a positive effect on patient treatment, with multiple large-scale clinical trials demonstrating the efficacy of SGLT2 inhibitors in reducing the risk of major adverse cardiovascular events, cardiovascular death, myocardial infarction, heart failure hospitalization, and all-cause mortality, as well as improving renal outcomes in T2DM patients with cardiovascular disease or at high cardiovascular risk (8–11).